Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced upcoming presentations of its AI/ML-driven predictive computational research at two major scientific conferences. The first presentation will be at the 2025 Annual Congress of the European Association for Cancer Research in Lisbon, Portugal (June 16-19), focusing on predicting immune evasion and immunotherapy resistance in TNBC subtypes. The second presentation will take place at the International Society for Computational Biology conference in Liverpool, UK (July 20-24), addressing computational prediction of TNBC tumor subtypes using single cell atlas analysis. Both presentations highlight Compugen's expertise in using computational methods to understand complex cancer biology. The posters will be made available on Compugen's website after the presentations.

HOLON, Israel, June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen's scientific capabilities in understanding complex cancer biology.

Poster details:

Conference: 2025 Annual Congress of the European Association for Cancer Research, June 16-19 Lisbon, Portugal
Poster number: EACR25-3113
Title: Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes
Presenting author: Amir Toporik, Computational Discovery, Compugen
Date of presentation: June 18, 2025 

Conference: International Society for Computational Biology and European Conference on Computational Biology- Annual International Conference on Intelligent Systems for Molecular Biology, July 20-24, 2025, Liverpool, UK
Poster number: 947
Title: Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms
Presenting author: Itamar Borukhov, Ph.D., Computational Discovery, Compugen

Posters will be available in the publications section of Compugen's website, www.cgen.com, following presentation.

About Compugen 
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen^TM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-aiml-driven-predictive-computational-research-at-upcoming-international-scientific-conferences-302480072.html

SOURCE Compugen Ltd.

FAQ

What will Compugen (CGEN) present at the 2025 EACR Congress in Lisbon?

Compugen will present research on predicting immune evasion and immunotherapy resistance mechanisms in TNBC subtypes, with poster number EACR25-3113, presented by Amir Toporik on June 18, 2025.

When and where will Compugen (CGEN) present at the ISCB-ECCB conference in 2025?

Compugen will present at the ISCB-ECCB conference in Liverpool, UK, from July 20-24, 2025, showcasing computational predictions of TNBC tumor subtypes using single cell atlas analysis.

What type of technology is Compugen using in their cancer research presentations?

Compugen is using AI/ML (Artificial Intelligence/Machine Learning) driven predictive computational research to understand complex cancer biology.

Where can investors find Compugen's conference presentation materials?

The presentation posters will be available in the publications section of Compugen's website (www.cgen.com) following the conferences.